2007 to 2023 Saw Decline in Menopausal Hormone Therapy Usage Rates
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 10, 2024 -- Menopausal hormone therapy (HT) usage rates declined from 2007 to 2023 and remain low, according to a study presented at the annual meeting of The Menopause Society, held from Sept. 10 to 14 in Chicago.
Mariam Saadedine, M.D., from the Mayo Clinic in Jacksonville, Florida, and colleagues described systemic menopausal HT utilization in women aged 40 years and older between 2007 and 2023 using claims data from the OptumLabs data warehouse. The annual rate of HT utilization was defined as the proportion of women with at least 180 days of a filled prescription for systemic estrogen-containing menopausal HT within one year.
The study population increased from about 2 million in 2007 to 4.5 million in 2023. The researchers found that among women aged 40 years or older, HT use was 4.6 percent in 2007, decreased to 2.5 percent between 2007 and 2014, and continued decreasing, reaching 1.8 percent in 2023. The most common route of administration was oral. HT use decreased from 3.2, 6, and 7.3 percent in 2007 to 1.5, 3.6, and 3.8 percent in 2023 among women aged 45 to 49, 50 to 54, and 55 to 59 years.
"These findings suggest that substantial barriers to HT use remain, and additional efforts are needed to educate women and clinicians about menopause management and HT use more specifically," coauthor Stephanie Faubion, M.D., medical director of The Menopause Society, said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Plant-Based Diet Tied to Weight Loss, Fewer Hot Flashes in Postmenopausal Women
THURSDAY, June 5, 2025 -- A plant-based diet rich in soy, regardless of the level of processing, may benefit both hot flash and weight management in postmenopausal women...
ASCO: Elinzanetant Cuts Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
TUESDAY, June 3, 2025 -- For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a...
Earlier Natural Menopause Risk Increased for Women in Socially Vulnerable Neighborhoods
THURSDAY, May 29, 2025 -- Women residing in U.S. neighborhoods with high social vulnerability have a higher risk for earlier natural menopause, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.